Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
0.2780 x 10 0.2910 x 7
Post-market by (Cboe BZX)
0.2863 +0.0087 (+3.13%) 04/17/25 [NASDAQ]
0.2780 x 10 0.2910 x 7
Post-market 0.2829 -0.0034 (-1.19%) 17:40 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2703
Day High
0.2950
Open 0.2715
Previous Close 0.2776 0.2776
Volume 575,100 575,100
Avg Vol 1,168,070 1,168,070
Stochastic %K 51.96% 51.96%
Weighted Alpha -44.06 -44.06
5-Day Change +0.0263 (+10.12%) +0.0263 (+10.12%)
52-Week Range 0.1800 - 1.7400 0.1800 - 1.7400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,893
  • Shares Outstanding, K 100,917
  • Annual Sales, $ 29,620 K
  • Annual Income, $ -47,580 K
  • EBIT $ -113 M
  • EBITDA $ -112 M
  • 60-Month Beta 0.87
  • Price/Sales 0.95
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.23
  • Most Recent Earnings $-0.08 on 03/17/25
  • Next Earnings Date 05/05/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 618.70% ( -225.37%)
  • Historical Volatility 114.86%
  • IV Percentile 96%
  • IV Rank 56.65%
  • IV High 1,051.52% on 04/04/25
  • IV Low 53.20% on 08/21/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 16
  • Volume Avg (30-Day) 355
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 17,821
  • Open Int (30-Day) 16,876

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.02
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +109.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2300 +24.48%
on 04/09/25
Period Open: 0.4450
0.3946 -27.45%
on 03/18/25
-0.1587 (-35.66%)
since 03/17/25
3-Month
0.2300 +24.48%
on 04/09/25
Period Open: 0.5728
0.8775 -67.37%
on 02/20/25
-0.2865 (-50.02%)
since 01/17/25
52-Week
0.1800 +59.06%
on 11/13/24
Period Open: 1.2700
1.7400 -83.55%
on 05/07/24
-0.9837 (-77.46%)
since 04/17/24

Most Recent Stories

More News
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FGEN : 0.2863 (+3.13%)
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FGEN : 0.2863 (+3.13%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 0.2863 (+3.13%)
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.2863 (+3.13%)
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.2863 (+3.13%)
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FGEN : 0.2863 (+3.13%)
FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen appoints David DeLucia as Chief Financial Officer, effective December 16, 2024, following Juan Graham's departure.Quiver AI SummaryFibroGen, Inc. has appointed David DeLucia as the new Chief Financial...

FGEN : 0.2863 (+3.13%)
FibroGen Appoints David DeLucia as Chief Financial Officer

FGEN : 0.2863 (+3.13%)
FibroGen: Q3 Earnings Snapshot

FibroGen: Q3 Earnings Snapshot

FGEN : 0.2863 (+3.13%)
FibroGen Reports Third Quarter 2024 Financial Results

FGEN : 0.2863 (+3.13%)

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 0.3221
2nd Resistance Point 0.3086
1st Resistance Point 0.2974
Last Price 0.2863
1st Support Level 0.2727
2nd Support Level 0.2592
3rd Support Level 0.2480

See More

52-Week High 1.7400
Fibonacci 61.8% 1.1441
Fibonacci 50% 0.9600
Fibonacci 38.2% 0.7759
Last Price 0.2863
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro